s6y

NuCana plc

Nasdaq
NCNA
CIK
1709626
Industry
Pharmaceutical Preparations
Based in
United Kingdom
Incorporated in
United Kingdom
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer
Formerly
NuCana BioMed Ltd

Key figures

Fiscal year to Dec 2025 Dec 2024 Dec 2023 Dec 2022 Dec 2021
Operating income −£20.1M−£22.8M−£32.8M−£39.1M−£47.9M
Net income −£29.4M−£19.0M−£27.6M−£32.0M−£40.5M
Diluted EPS £0.00−£0.26−£0.53−£0.61−£0.78
Cash from operations −£7.47M−£19.1M−£26.4M−£23.2M−£23.8M
Total assets £29.8M£14.8M£27.8M£58.3M£77.5M
Shareholders’ equity £24.3M£5.95M£14.9M£38.5M£65.5M

From the company’s annual reports to the SEC, in GBP. Each year links to its report.

Financials 9

  1. 20-F Annual report (foreign issuer) for period ending Dec 31, 2025
  2. 20-F Annual report (foreign issuer) for period ending Dec 31, 2024
  3. 20-F Annual report (foreign issuer) for period ending Dec 31, 2023
  4. 20-F Annual report (foreign issuer) for period ending Dec 31, 2022
  5. 20-F Annual report (foreign issuer) for period ending Dec 31, 2021
  6. 20-F Annual report (foreign issuer) for period ending Dec 31, 2020
  7. 20-F Annual report (foreign issuer) for period ending Dec 31, 2019
  8. 20-F Annual report (foreign issuer) for period ending Dec 31, 2018
  9. 20-F Annual report (foreign issuer) for period ending Dec 31, 2017

News 139

  1. 6-K Current report (foreign issuer)
  2. 6-K Current report (foreign issuer)
  3. 6-K Current report (foreign issuer)
  4. 6-K Current report (foreign issuer)
  5. 6-K Current report (foreign issuer)
  6. 6-K Current report (foreign issuer)
  7. 6-K Current report (foreign issuer)
  8. 6-K Current report (foreign issuer)
  9. 6-K Current report (foreign issuer)
  10. 6-K Current report (foreign issuer)

All 139 news filings

Ownership 69

  1. 4 Levy Elliott M.: Change in insider ownership
  2. 4 Change in insider ownership
  3. 4 Change in insider ownership
  4. 3 Initial statement of insider ownership
  5. 3 Initial statement of insider ownership
  6. 3 Initial statement of insider ownership
  7. 3 Initial statement of insider ownership
  8. SCHEDULE 13D Major shareholder report
  9. 3 Initial statement of insider ownership
  10. 3 Initial statement of insider ownership

All 69 ownership filings

Prospectus 17

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  4. DRSLTR Correspondence Related to Draft Registration Statement
  5. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 17 prospectus filings

Other 50

  1. F-6 POS Post-effective amendment to a F-6EF registration
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. F-3/A Registration statement for specified transactions by certain foreign private issuers
  5. UPLOAD Letter (PDF)
  6. EFFECT Notice of Effectiveness
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. F-1/A Registration statement for securities of certain foreign private issuers

All 50 other filings

Others in Pharmaceutical Preparations

Every company in this industry